Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland

References

• Rees J. The characteristics of an enigmatic disease. Psoriasis Pract 2002;1:1–3
   Google Scholar
• Berth-Jones J. Psoriasis. Medicine 2005;33:50–55
   Google Scholar
• Lebwohl M. Psoriasis. Lancet 2003;361:1197–204
   PubMed Web of Science ®Google Scholar
• Henseler T, Christophers E. Psoriasis of early and late onset: characterisation of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450–6
   PubMed Web of Science ®Google Scholar
• Smith AE, Kassab J, Payne C, et al. Bimodality in age of onset of psoriasis, in both patients and their relatives. Dermatology 1993;186:181–6
   PubMed Web of Science ®Google Scholar
• Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42:796–802
   PubMed Web of Science ®Google Scholar
• Rapp S, Feldman S, Exum M, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401–7
   PubMed Web of Science ®Google Scholar
• Zachariare R, Zachariare H, Blomqvist K, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002;146:1006–16
   PubMed Web of Science ®Google Scholar
• Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1–18
   PubMedGoogle Scholar
• Julian CG. Dermatology in general practice. Br J Dermatol 1999;141:518–20
   PubMed Web of Science ®Google Scholar
• Cork M. Economic considerations in the treatment of psoriasis. Dermatol Pract 1993;1:16–20
   Google Scholar
• Harris DW, Benton EC, Hunter JA. The changing face of dermatology outpatient referrals in the south-east of Scotland. Br J Dermatol 1990;123:745–50
   PubMed Web of Science ®Google Scholar
• CompuFile Ltd. DIN-LINK report: Body and scalp psoriasis February, 2005
   Google Scholar
• Dawe, R, Wainwright NJ, Cameron H, et al. Narrow band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 1998;138:833–9
   PubMed Web of Science ®Google Scholar
• Summary Report of Expert Findings, 21 March 2005. Data on file
   Google Scholar
• Dermatology – Psoriasis Patient Pathway April 2005 http://www.pathways.scot.nhs.uk/Dermatology/Dermatology%20Pso riasis%2023Sep05.htm [accessed on 20 October 2006]
   Google Scholar
• Kragballe K, Barnes L, Hamberg KJ, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998;139:649–54
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268–9
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomised study. Br J Dermatol 1998;138:254–8
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol 1997;37:S55–8
   PubMedGoogle Scholar
• Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/ betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131–5
   PubMed Web of Science ®Google Scholar
• Guenther L, Cambazard F, van de Kerkhof PCM, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomised, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316–23
   Google Scholar
• Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48–54
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate (Daivobet) is an effective once daily treatment for psoriasis vulgaris. Dermatology 2002;205:389–93
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004;150:1167–73
   PubMed Web of Science ®Google Scholar
• Ortonne J-P, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004;209:308–13
   Google Scholar
• Van de Kerkhof PCM. A fixed combination of calcipotriol/ betamethasone dipropionate improves quality of life. Abstract presented at EADV (European Academy of Dermatology and Venereology) Prague, 2002
   Google Scholar
• Nørregaard J, Lowson D. The cost utility of calcipotriol/ betamethasone (Dovobet^®) ointment in the treatment of psoriasis vulgaris in the United Kingdom (abstract). Value Health 2003;6:785
   Google Scholar
• Kragballe K, van de Kerkhof PCM. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006;20:39–44
   PubMed Web of Science ®Google Scholar
• Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British Health Service. JAMA 2005;294:2618–22
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437–52
   PubMed Web of Science ®Google Scholar
• Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgements. BMJ 2004;329:224–7
   PubMed Web of Science ®Google Scholar
• Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998;38:1010–11
   PubMed Web of Science ®Google Scholar
• Gordon K, Feldman S, Koo J, et al. Definitions of measures of effect duration for psoriasis treatments. Psoriasis Forum 2002;8:1–3
   Google Scholar
• Anstey AV, Kragballe K. A retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol 2006;45:970–5
   PubMed Web of Science ®Google Scholar
• Song F, Altman D, Glenny A-M, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472–6
   Google Scholar
• Data on file. (Clinical Study Report MC 9302 INT: 1997)
   Google Scholar
• Mason J, et al. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146:351–64
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Camp RDR, Barker JNWN. Psoriasis. In: Burns DA, Breathnach SM, Cox NH, Griffiths CEM, eds. Rook’s Textbook of Dermatology, 7th edn, Vol 2. Oxford: Blackwell Publishing, 2004:35.1–35.69
   Google Scholar
• www.show.scot.nhs.uk/waiting/
   Google Scholar
• Marchetti A, LaPensee K, An P. A pharmacoeconomic analysis of topical therapies for patients with mild to moderate stable plaque psoriasis: A US study. Clin Ther 1998;20:851–69
   Google Scholar
• Monthly Index of Medical Specialities February 2007
   Google Scholar
• Curtis L, Netten A. Unit Costs of Health & Social Care 2006. http://www.pssru.ac.uk/uc/uc2006contents.htm (Accessed 7 March 2007)
   Google Scholar
• Scotland Health Service Costs 2006. Specialty Group Costs – Outpatients. Consultant Clinics. Report 044. Section 6B. Outpatients (Dermatology). See http://www.isdscotland.org/isd/information.jsp?pContentID=3583&p_applic=CCC&p_service=Content.show& [Accessed on 15 March 2007]
   Google Scholar
• Scotland Health Service Costs 2006. Specialty Group Costs – Outpatient Nurse Led Clinics. Report 045. Outpatients (Dermatology). See http://www.isdscotland.org/isd/information.jsp?pContentID=3583&p_applic=CCC&p_service=Content.show& [Accessed on 15 March 2007]
   Google Scholar
• Kind P. The EuroQol instrument: an index of health-related quality of life In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996
   Google Scholar
• Oh PI, Gupta AK, Einarson TR, et al. Calcipotriol in the treatment of psoriasis of limited severity: pharmacoeconomic evaluation. J Cutan Med Surg 1997;2:7–15
   Google Scholar
• Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067–75
   PubMed Web of Science ®Google Scholar
• Jacobson CC, Kimball AB. Rethinking the psoriasis area and severity index: the impact of area should be increased. Br J Dermatol 2004;151:381–7
   PubMed Web of Science ®Google Scholar
• Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9(26):1–134
   PubMed Web of Science ®Google Scholar
• Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897–900
   Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–24
   PubMed Web of Science ®Google Scholar
• Guide to the methods of technology appraisal review process and timelines. 16 April 2007;National Institute for Health and Clinical Excellence. See http://www.nice.org.uk [Accessed 16 April 2007]
   Google Scholar
• Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52 week, randomized, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet®/Dovobet®/Taclonex®) in the treatment of psoriasis vulgaris. Dermatology 2006;213:319–26
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet®/Dovobet®/Taclonex®) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155–60
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46):1–252
   PubMed Web of Science ®Google Scholar
• ACD Psoriasis – efalizumab and etanercept [accessed on www.nice.org.uk on 6 September 2005]
   Google Scholar
• Etanercept and efalizumab for the treatment of adults with psoriasis. NICE Technology Appraisal Guidance 103. July 2006. Accessed on www.nice.org.uk on 15 March 2007]
   Google Scholar
• Peeters P, Ortonne J-P, Sitbon R, et al. Cost effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology 2005;211:139–45
   Google Scholar